Lymphoma, Mantle-Cell: all 810 studies
Page 7 of 9. Open to participants first (149), then studies with results posted, then the rest; newest registration first within each.
- Everolimus and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Hematologic CancerCompletedNCT02240719Phase 1
- Safety Study of SGN-CD70A in Cancer PatientsCompletedNCT02216890Phase 1
- Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Participants With Relapsed or Refractory Mantle Cell LymphomaCompletedNCT02169180Phase 2
- CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin LymphomaTerminatedNCT02168907Phase 1
- Ibrutinib and Palbociclib in Treating Patients With Previously Treated Mantle Cell LymphomaActive, not recruitingNCT02159755Phase 1
- Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic LeukemiaActive, not recruitingNCT02153580Phase 1
- Carfilzomib Plus Belinostat in Relapsed/Refractory NHLCompletedNCT02142530Phase 1
- Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV InfectionTerminatedNCT02109224Phase 1
- CART-19 Immunotherapy in Mantle Cell LymphomaStatus unknownNCT02081937Phase 1/2
- Memory Enriched T Cells Following Stem Cell Transplant in Treating Patients With Recurrent B-Cell Non-Hodgkin LymphomaActive, not recruitingNCT02051257Phase 1
- Study of BKM120 & Rituximab in Patients With Relapsed or Refractory Indolent B-Cell LymphomaCompletedNCT02049541Phase 1
- Ublituximab + Ibrutinib in Select B-cell MalignanciesCompletedNCT02013128Phase 1/2
- Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological DiseasesTerminatedNCT01962636Not applicable
- Dose Monitoring of Busulfan and Combination Chemotherapy in Hodgkin or Non-Hodgkin Lymphoma Undergoing Stem Cell TransplantCompletedNCT01959477Early Phase 1
- Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin LymphomaActive, not recruitingNCT01955499Phase 1
- Rituximab Maintenance Therapy in Aggressive CD20 (Cluster of Differentiation Antigen 20) Positive Lymphoma and Mantle Cell LymphomaStatus unknownNCT01933711Phase 3
- Carfilzomib Consolidation Therapy After Autologous Stem Cell Transplantation (ASCT) for Mantle Cell Lymphoma (MCL), T-cell Lymphoma (TCL), and Diffuse Large B-Cell Lymphoma (DLBCL)CompletedNCT01926665Phase 1
- Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell LymphomasCompletedNCT01897012Phase 1
- Ibrutinib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Older Patients With Newly Diagnosed Mantle Cell LymphomaActive, not recruitingNCT01880567Phase 2
- R-CHOP + R-HAD vs R-CHOP Followed by Maintenance Lenalidomide + Rituximab vs Rituximab for Older Patients With MCLCompletedNCT01865110Phase 3
- Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by CART19Status unknownNCT01864889Not applicable
- Phase 1/2 Study of VSLI Plus Rituximab in Patients With Relapsed and/or Refractory NHLCompletedNCT01851551Phase 1/2
- Lenalidomide With or Without Idelalisib in Treating Patients With Relapsed or Refractory Mantle Cell LymphomaCompletedNCT01838434Phase 1
- An Open Label Treatment Use Protocol for Ibrutinib in Subjects With Relapsed or Refractory Mantle Cell LymphomaApproved for marketingNCT01833039
- Infusion of Depleted T Cells Following Unrelated Donor Stem Cell Transplant (ICAT)CompletedNCT01827579Phase 1/2
- Genetically Modified T-cell Infusion Following Peripheral Blood Stem Cell Transplant in Treating Patients With Recurrent or High-Risk Non-Hodgkin LymphomaActive, not recruitingNCT01815749Phase 1
- A Long-term Extension Study of PCI-32765 (Ibrutinib)Active, not recruitingNCT01804686Phase 3
- A Safety Study of SGN-CD19A for B-Cell LymphomaCompletedNCT01786135Phase 1
- Genetically Modified Peripheral Blood Stem Cell Transplant in Treating Patients With HIV-Associated Non-Hodgkin or Hodgkin LymphomaWithdrawnNCT01769911Not applicable
- MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or LymphomaCompletedNCT01748721Phase 1
- Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid MalignanciesTerminatedNCT01744912Phase 1
- Bendamustine/Lenalidomide/Rituximab: Combination as a Second-Line Therapy for 1st Relapsed-Refractory MCLCompletedNCT01737177Phase 2
- Genetically Engineered Lymphocyte Therapy in Treating Patients With Lymphoma That is Resistant or Refractory to ChemotherapyStatus unknownNCT01735604Phase 1/2
- Phase I Dose Escalation Study of IMMU-114 in Relapsed or Refractory NHL and CLLTerminatedNCT01728207Phase 1
- Buparlisib in Treating Patients With Relapsed or Refractory Non-Hodgkin LymphomaCompletedNCT01719250Early Phase 1
- Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin LymphomaActive, not recruitingNCT01695941Phase 1
- 131I-rituximab for Relapsed or Refractory Follicular or Mantle Cell LymphomaStatus unknownNCT01678417Phase 2
- Phase II Study of Age-Adjusted Rituximab, Bendamustine, Cytarabine as Induction Therapy in Older Patients With MCLCompletedNCT01662050Phase 2
- Methoxyamine and Fludarabine Phosphate in Treating Patients With Relapsed or Refractory Hematologic MalignanciesCompletedNCT01658319Phase 1
- A Phase II Study of AT7519M, a CDK Inhibitor, in Patients With Relapsed Mantle Cell LymphomaCompletedNCT01652144Phase 2
- Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic MalignanciesWithdrawnNCT01652014Phase 2
- A Study to Evaluate the Efficacy and Safety of Ibrutinib, in Patients With Mantle Cell Lymphoma Who Progress After Bortezomib TherapyCompletedNCT01599949Phase 2
- Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell TransplantCompletedNCT01588015Phase 1
- Vorinostat Plus FND in Relapsed or Refractory Mantle Cell LymphomaTerminatedNCT01578343Phase 2
- Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell LymphomaCompletedNCT01567709Phase 1
- Study to Evaluate Efficacy and Tolerance of R-GemOx in DLBCL and MCLCompletedNCT01562977Phase 2
- Mechanical Stimulation in Preventing Bone Density Loss in Patients Undergoing Donor Stem Cell TransplantWithdrawnNCT01558778Not applicable
- Donor Peripheral Stem Cell Transplant in Treating Patients With Hematolymphoid MalignanciesCompletedNCT01523223Phase 1
- Phase I Study of Panobinostat + Bortezomib for Relapsed and/or Refractory Mantle Cell Lymphoma (MCL)CompletedNCT01504776Phase 1
- A Pilot Study of Oral Vorinostat Plus Oral Eltrombopag Support in Patients With Lymphoma (VEIL)TerminatedNCT01500538Phase 2
- Sequential Chemo-Radioimmunotherapy Followed by Autologous Transplantation for Patients With Untreated Advanced Stage Mantle Cell LymphomaCompletedNCT01484093Phase 1/2
- Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile NeutropeniaCompletedNCT01484015Phase 1
- Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's LymphomaActive, not recruitingNCT01479842Phase 1
- CD19 CAR T Cells for B Cell Malignancies After Allogeneic TransplantCompletedNCT01475058Phase 1/2
- Velcade, Nipent, Rituxan (VNR) in Subjects With Relapsed Follicular, Marginal Zone, and Mantle Cell LymphomaWithdrawnNCT01460602Phase 1/2
- A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic CancersCompletedNCT01460134Phase 1
- Study of Mantle Cell Lymphoma Treatment by RiBVDCompletedNCT01457144Phase 2
- Bendamustine Plus Rituximab Versus Fludarabine Plus RituximabCompletedNCT01456351Phase 3
- Efficacy and Safety of R-HAD Alone or in Combination With Bortezomib in Patients With Relapsed or Refractory MCLStatus unknownNCT01449344Phase 3
- Bortezomib (VELCADE), Cladribine and Rituximab (VCR) in Mantle Cell Lymphoma (PSHCI 10-011)Status unknownNCT01439750Phase 1
- Safety and Tolerability Study of SNS01-T in Relapsed or Refractory B Cell Malignancies (Multiple Myeloma, B Cell Lymphoma, or Plasma Cell Leukemia (PCL)Status unknownNCT01435720Phase 1/2
- Study Combining SAR245409 With Rituximab or Bendamustine Plus Rituximab in Patients With Indolent Lymphoma, Mantle Cell Lymphoma and Chronic Lymphocytic LeukemiaCompletedNCT01410513Phase 1
- Study of BMN 673, a PARP Inhibitor, in Patients With Advanced Hematological MalignanciesCompletedNCT01399840Phase 1
- Escalating Doses of Torisel in Combination With Three Chemotherapies Regimens: R-CHOP, R-FC or R-DHA for Patients With Relapsed/Refractory Mantle Cell Lymphoma (MCL).CompletedNCT01389427Phase 1/2
- Study of CEP-9722 in Combination With Gemcitabine and Cisplatin in Patients With Advanced Solid Tumors or Mantle Cell LymphomaCompletedNCT01345357Phase 1
- Combination of Bortezomib, Fludarabine and Cyclophosphamide Treat Recurrent Mantle Cell LymphomaStatus unknownNCT01322776Phase 1/2
- AMG 319 Lymphoid Malignancy FIHCompletedNCT01300026Phase 1
- Nonmyeloablative Allogeneic TransplantCompletedNCT01272817Not applicable
- A Safety and Efficacy Study of SB1518 for the Treatment of Advanced Lymphoid MalignanciesCompletedNCT01263899Phase 2
- Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic CancersCompletedNCT01254578Phase 1
- Vaccine Therapy With or Without Cryosurgery in Treating Patients With Residual, Relapsed, or Refractory B-Cell Non-Hodgkin LymphomaCompletedNCT01239875Early Phase 1
- Obatoclax Mesylate, Rituximab, and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Non-Hodgkin LymphomaWithdrawnNCT01238146Phase 1/2
- MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or LeukemiaCompletedNCT01231919Phase 1
- Dexamethasone, Ofatumumab and Bendamustine (DOT) First-line in Mantle-cell Lymphoma(MCL)Status unknownNCT01221103Phase 1/2
- Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell TransplantActive, not recruitingNCT01199562
- High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin LymphomaCompletedNCT01177371Phase 2
- Bendamustine and Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Non-Hodgkin's Lymphoma (NHL)WithdrawnNCT01170052Phase 1/2
- T-Regulatory Cell and CD3 Depleted Double Umbilical Cord Blood Transplantation in Hematologic MalignanciesWithdrawnNCT01163201Phase 1/2
- RO4929097 and Capecitabine in Treating Patients With Refractory Solid TumorsCompletedNCT01158274Phase 1
- Study of Canfosfamide in Refractory or Relapsed Mantle Cell, Diffuse Large B Cell Lymphoma and Multiple MyelomaCompletedNCT01148108Phase 2
- AR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or LymphomaCompletedNCT01129193Phase 1
- A Study of the Kinetics of Lymphoid Cells in Patients With Monoclonal B-cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL), Mantle Cell Lymphoma (MCL) and Healthy VolunteersCompletedNCT01117142
- Vorinostat and Lenalidomide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin LymphomaTerminatedNCT01116154Phase 1
- Trial of PD 0332991 Plus Bortezomib in Patients With Relapsed Mantle Cell LymphomaTerminatedNCT01111188Phase 1
- Temsirolimus, Bendamustine and Rituximab for Relapsed Follicular Lymphoma or Mantle Cell LymphomaCompletedNCT01078142Phase 1/2
- Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for CancerCompletedNCT01053494Not applicable
- Lenalidomide And Rituximab as Maintenance Therapy in Treating Patients With B-Cell Non-Hodgkin LymphomaTerminatedNCT01045928Phase 1
- Collecting and Storing Tissue Samples From Patients With Rare or Cutaneous Non-Hodgkin LymphomaCompletedNCT01000753
- Immunochemotherapy With Rituximab-Bendamustine-Cytarabine (R-BAC) for Patients With Mantle Cell LymphomaCompletedNCT00992134Phase 2
- Lenalidomide, Bendamustine and Rituximab as First-line Therapy for Patients Over 65 Years With Mantle Cell Lymphoma.CompletedNCT00963534Phase 1/2
- Prospective Trial on Immunochemotherapy Plus Autologous Stem Cell Transplantation (SCT) and Allogenic SCT in Primary Mantle-Cell-LymphomaStatus unknownNCT00946374Phase 2
- 3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With CancerActive, not recruitingNCT00935090
- Mantel Cell Lymphoma Efficacy of Rituximab MaintenanceCompletedNCT00921414Phase 3
- Lenalidomide and R-CHOP in B-cell LymphomaCompletedNCT00901615Phase 1/2
- Studying Fentanyl in Patients With CancerTerminatedNCT00899951
- Gossypol, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by SurgeryCompletedNCT00891072Phase 1
- Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral TherapyCompletedNCT00890747Phase 1
- Fludarabine, Bendamustine, and Rituximab in Treating Participants With Lymphoid Cancers Undergoing Stem Cell TransplantCompletedNCT00880815Phase 1
- Significance of Duration of Maintenance Therapy With Rituximab in Non-Hodgkin LymphomasActive, not recruitingNCT00877214Phase 3
- SCH 727965 in Patients With Mantle Cell Lymphoma or B-Cell Chronic Lymphocytic Leukemia (Study P04715)TerminatedNCT00871546Phase 2